Alerta

交联的V型胶原蛋白测定法

Resumen de: WO2024008796A1

The present invention relates to a sandwich immunoassay for detecting in a biological sample cross-linked Collagen Type V, and its use in identifying patients with conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing the sandwich immunoassay.

一种抗血红蛋白的抗体及其应用

Resumen de: CN119529078A

本发明公开了一种抗血红蛋白的抗体及其应用，涉及抗体领域。本发明公开的抗血红蛋白抗体包括重链互补决定区和轻链互补决定区，该抗体为血红蛋白的检测提供了重要的原料来源，且具有良好的活性和灵敏度。

FECAL SAMPLE, BREATH SAMPLE COLLECTION AND ANALYSIS FOR TREATING INFLAMMATORY BOWEL DISEASE

Resumen de: US2025069692A1

The invention is related to a system for treating irritable bowel syndrome, Crohn's disease, ulcerative colitis (collectively, inflammatory bowel disease, or “IBD”) by determining a number of indicators, including genetic markers, gene expression levels, levels of certain compounds in the gut or feces, hydrogen and/or methane levels, and concentrations of particular bacteria in the gut or feces, and correlating one or more such indicators with symptoms in test subjects with IBD; and correlating diet, drugs, supplements or other therapy, with alleviation of IBD symptoms. The correlations established in the test subjects are confirmed or refuted for individuals suffering IBD, and the treatments established as reducing symptoms are supported through messaging and compliance is verified by monitoring the indicators.

METHODS OF DIAGNOSING IBS-D AND SELECTION OF IBS-D TREATMENT

Resumen de: AU2023257366A1

The present invention describes methods of detecting IBS-D. Further described are methods selecting a therapy and methods of treatment for IBS-D. These methods are based, at least in part, on a subject's level of Desulfovibrio, Fusobacterium, or hydrogen sulfide.

Difunctional fluorescent array sensor, preparation method thereof and application of difunctional fluorescent array sensor in bacterial detection and fermentative carbohydrate detection

Resumen de: CN119510374A

The invention relates to a fluorescent array sensor, in particular to a difunctional fluorescent array sensor containing a modified high-molecular polymer, a preparation method of the difunctional fluorescent array sensor and application of the difunctional fluorescent array sensor in bacterial detection and fermentation carbohydrate detection. The array sensor comprises at least two different fluorescent sensing units, each fluorescent sensing unit is a PN-coumarin dye compound formed by covalent interaction of PN and coumarin dye, PN is a nitrophenylboronic acid modified high-molecular polymer PEI, the coumarin dye is 6, 7-diphenyl-1, 3, 4-triazole-3-carboxylic acid, and the coumarin dye is a coumarin dye compound. The compound is selected from the group consisting of 2, 7-dihydroxy-2H-benzopyran-2-one ES or 4-methylesculetin MS. The compound fluorescent array sensor disclosed by the invention can simultaneously realize distinguishing detection of thirteen types of bacteria related to IBS and fourteen FODMAPs, and has the advantages of high sensitivity, short detection time, low cost, good repeatability, high accuracy, no need of professional technicians and the like.

BAZ2B作为靶点在非酒精性脂肪肝以及肝炎中的应用

Resumen de: CN119488592A

本申请涉及BAZ2B作为靶点在非酒精性脂肪肝以及肝炎中的应用。更具体的，本申请涉及用于调节BAZ2B表达或活性的药剂，如BAZ2B的下调剂；包含所述调节BAZ2B表达或活性的药剂的组合物；以及调节BAZ2B在细胞中表达水平或活性的方法，例如抑制BAZ2B的表达或活性的方法。本申请还涉及通过调节BAZ2B在细胞中表达水平或活性，从而治疗或改善肝脏疾病的方法，所述肝脏疾病例如包括与脂类代谢相关的疾病、非酒精性脂肪性肝病(nonalcoholic fatty liver disease，NAFLD)、非酒精性脂肪性肝炎(non‑alcoholic steatohepatitis，NASH)和肥胖。

DIETARY MACRO/MICRONUTRITIONAL COMPOSITIONS AND APPLICATIONS THEREOF

Resumen de: US2025057842A1

Provided herein are compositions composed of a plurality of minerals and vitamins that provide numerous health benefits and quality of life to subjects in need thereof. Also described herein are kits composed of the compositions described herein with a marine omega 3 fatty acid, coenzyme Q10, or a combination thereof. In one aspect, the compositions described herein can treat a subject diagnosed with prediabetes, type 1 diabetes, type 2 diabetes or insulin uptake. In another aspect, the compositions described herein can increase the performance of athletes by relaxing and dilating blood vessels, thus improve circulation as well as shorten the time of recovery after exercises or games. In another aspect, the compositions described herein can improve the well-being and immune response system. It also improves the human system against bacterial and fungal infections. In another aspect, the compositions described herein can treat myalgic encephalomyelitis in a subject. In another aspect, the compositions described herein can reduce or prevent one or more symptoms of Crohn's disease in a subject. In another aspect, the compositions described herein can enhance one or more physical properties of a subject after exercise.

METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNF ALPHA THERAPY IN INFLAMMATORY BOWEL DISEASE

Resumen de: US2025059605A1

The present invention relates to methods of prognosing responsiveness to anti-TNFα therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNFα therapy in an individual diagnosed with IBD.

PROSTATE-SPECIFIC MEMBRANE ANTIGEN AS AN IMAGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE

Resumen de: WO2025038942A1

Disclosed are methods for imaging inflammation associated with inflammatory bowel disease (IBD), including administering to a subject a prostate-specific membrane antigen (PSMA)-targeted imaging agent and taking an image.

BACTERIAL BIOSENSORS FOR DIAGNOSING AND TREATING INFLAMMATION

Nº publicación: EP4508236A1 19/02/2025

Solicitante:

BAYLOR COLLEGE MEDICINE [US]
Baylor College of Medicine

Resumen de: WO2023201243A1

Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and/or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.